Pharmacogenomics of amlodipine and hydrochlorothiazide therapy and the quest for improved control of hypertension : a mini review

Simple item page
dc.contributor.authorJohnson, Rabiaen_ZA
dc.contributor.authorDludla, Phiwayinkosien_ZA
dc.contributor.authorMabhida, Sihleen_ZA
dc.contributor.authorBenjeddou, Mongien_ZA
dc.contributor.authorLouw, Johanen_ZA
dc.contributor.authorFebruary, Faghrien_ZA
dc.date.accessioned2021-10-28T07:45:31Z
dc.date.available2021-10-28T07:45:31Z
dc.date.issued2019
dc.descriptionCITATION: Johnson, R., et al. 2019. Pharmacogenomics of amlodipine and hydrochlorothiazide therapy and the quest for improved control of hypertension : a mini review. Heart Failure Reviews, 24:343-357, doi:10.1007/s10741-018-09765-y.
dc.descriptionThe original publication is available at https://link.springer.com
dc.description.abstractENGLISH ABSTRACT: Blood pressure (BP) is a complex trait that is regulated by multiple physiological pathways and include but is not limited to extracellular fluid volume homeostasis, cardiac contractility, and vascular tone through renal, neural, or endocrine systems. Uncontrolled hypertension (HTN) has been associated with an increased mortality risk. Therefore, understanding the genetics that underpins and influence BP regulation will have a major impact on public health. Moreover, uncontrolled HTN has been linked to inter-individual variation in the drugs’ response and this has been associated with an individual’s genetics architecture. However, the identification of candidate genes that underpin the genetic basis of HTN remains a major challenge. To date, few variants associated with inter-individual BP regulation have been identified and replicated. Research in this field has accelerated over the past 5 years as a direct result of on-going genome-wide association studies (GWAS) and the progress in the identification of rare gene variants and mutations, epigenetic markers, and the regulatory pathways involved in the pathophysiology of BP. In this review we describe and enhance our current understanding of how genetic variants account for the observed variability in BP response in patients on first-line antihypertensive drugs, amlodipine and hydrochlorothiazide.en_ZA
dc.description.urihttps://link.springer.com/article/10.1007%2Fs10741-018-09765-y
dc.description.versionPublisher's version
dc.format.extent15 pagesen_ZA
dc.identifier.citationJohnson, R., et al. 2019. Pharmacogenomics of amlodipine and hydrochlorothiazide therapy and the quest for improved control of hypertension : a mini review. Heart Failure Reviews, 24:343-357, doi:10.1007/s10741-018-09765-y
dc.identifier.issn1573-7322 (online)
dc.identifier.issn1382-4147 (print)
dc.identifier.otherdoi:10.1007/s10741-018-09765-y
dc.identifier.urihttp://hdl.handle.net/10019.1/123324
dc.language.isoen_ZAen_ZA
dc.publisherSpringeren_ZA
dc.rights.holderAuthors retain copyrighten_ZA
dc.subjectAmlodipineen_ZA
dc.subjectPharmacogenomicsen_ZA
dc.subjectSingle nucleotide polymorphismsen_ZA
dc.subjectHypertensionen_ZA
dc.subjectDiureticsen_ZA
dc.titlePharmacogenomics of amlodipine and hydrochlorothiazide therapy and the quest for improved control of hypertension : a mini reviewen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
johnson_pharmacogenomics_2019.pdf
Size:
596.13 KB
Format:
Adobe Portable Document Format
Description:
Download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Medical Physiology)